NanoViricides, Inc. Reports that Oral Administration of FluCide® Anti-Influenza Drug Candidates Led to Strong Antiviral Antibody Response in a Highly Lethal Animal Model

Published: Sep 04, 2012

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTCBB:NNVC) (the "Company") announced today that anti-influenza drug candidates under its FluCide™ program, when given orally, led to strong antiviral antibody response. The antibody response with Oral administration was stronger than that with IV administration and was substantially greater than that observed with oseltamivir.

Back to news